Impact of I/D polymorphism of ACE gene on risk of development and course of chronic obstructive pulmonary disease

Archives of Medical Science

Volumn 12, Issue 2, 2016, Pages 279-287

  Mlak, Radoslaw ^a   Homa Mlak, Iwona ^a   Powrózek, Tomasz ^a   Mackiewicz, Barbara ^a   Michnar, Marek ^a   Krawczyk, Pawel ^a   Dziedzic, Marcin ^a   Rubinsztajn, Renata ^b   Chazan, Ryszarda ^b   Milanowski, Janusz ^a   Malecka Massalska, Teresa ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

ACE polymorphism; Chronic obstructive pulmonary disease; Exacerbation; Renin angiotensin aldosterone system

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; SMOKING; VERY ELDERLY;

EID: 84963766560     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.50757     Document Type: Article

References (27)

1. Wozniak K, Sleszycka J, Safanowska A, Wiechno W, Domagala-Kulawik J. Systemic infammation in peripheral arterial disease with or without coexistent chronic obstructive pulmonary disease: analysis of selected markers. Arch Med Sci 2012; 8: 477-83.
2. Serapinas D, Sitkauskiene B, Sakalauskas R. Infamma-tory markers in chronic obstructive pulmonary disease patients with diferent alpha1 antitrypsin genotypes. Arch Med Sci 2012; 8: 1053-8.
3. Yawn BP. Is 'GOLD' standard for the management of COPD in clinical practice? Drugs Context 2012; 2012: 212243.
4. Pabst S, Theis B, Gillissen A, et al. Angiotensin-convert-ing enzyme I/D polymorphism in chronic obstructive pulmonary disease. Eur J Med Res 2009; 14: 177-81.
5. Bossé Y. Updates on the COPD gene list. Int J Chron Obstruct Pulmon Dis 2012; 7: 607-31.
6. Xiao M, Guo L, Wang T, et. al. Interleukin-1B-31T/C promoter polymorphism and chronic obstructive pulmonary disease risk: a meta-analysis. Arch Med Sci 2014; 10: 434-8.
7. Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci 2012; 123: 487-98.
8. Crowley SD, Cofman TM. Recent advances involving the renin-angiotensin system. Exp Cell Res 2012; 318: 1049-56.
9. Puthucheary Z, Skipworth JR, Rawal J, Loosemore M, Van Someren K, Montgomery HE. The ACE gene and human performance: 12 years on. Sports Med 2011; 41: 433-48.
10. Richard PM. The pulmonary renin-angiotensin system. Curr Pharm Des 2003; 9: 715-22.
11. Rieder MJ, Taylor SL, Clark AG, Nickerson DA. Sequence variation in the human angiotensin converting enzyme. Nat Genet 1999; 22: 59-62.
12. Lei H, Day IN, Vorechovský I. Exonization of AluYa5 in the human ACE gene requires mutations in both 3' and 5' splice sites and is facilitated by a conserved splicing enhancer. Nucleic Acids Res 2005; 33: 3897-906.
13. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
14. Kieszko R, Krawczyk P, Powrózek T, et al. The impact of ACE gene polymorphism on the incidence and phenotype of sarcoidosis in rural and urban settings. Arch Med Sci 2015; DOI: 10.5114/aoms.2015.48966.
15. Forth R, Montgomery H. ACE in COPD: a therapeutic target? Thorax 2003; 58: 556-8.
16. Spruit MA, Singh SJ, Garvey C, et al.; ATS/ERS Task Force on Pulmonary Rehabilitation. An ofcial American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 180: e13-64.
17. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res 2006; 98: 1123-33.
18. Busquets X, MacFarlane NG, Heine-Suñer D, et al. Angiotensin-converting-enzyme gene polymorphisms, smoking and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007; 2: 329-34.
19. Tkácová R, Joppa P, Stancák B, Salagovic J, Misíková S, Kalina I. The link between angiotensin-converting enzyme genotype and pulmonary artery pressure in patients with COPD. Wien Klin Wochenschr 2005; 117: 210-4.
20. Zhang X, Wang C, Dai H, Lin Y, Zhang J. Association between angiotensin-converting enzyme gene polymorphisms and exercise performance in patients with COPD. Respirology 2008; 13: 683-8.
21. Li X, Wei N, Wu Z, et al. The D/I polymorphism in the an-giotensin-converting enzyme gene and chronic obstructive pulmonary disease risk: a meta-analysis. COPD 2012; 9: 485-91.
22. Li W, Lan F, Yan F, Shen H. Angiotensin-converting enzyme I/D polymorphism is associated with COPD risk in Asian population: evidence from a meta-analysis. COPD 2013; 10: 35-9.
23. Lee J, Nordestgaard BG, Dahl M. Elevated ACE activity is not associated with asthma, COPD, and COPD co-morbidity. Respir Med 2009; 103: 1286-92.
24. Shaw JG, Dent AG, Passmore LH, et al. Genetic infuenc-es on right ventricular systolic pressure (RVSP) in chronic obstructive pulmonary disease (COPD). BMC Pulm Med 2012; 12: 25.
25. Celli BR. Predictors of mortality in COPD. Respir Med 2010; 104: 773-9.
26. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010; 19: 113-8.
27. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Re-spir Crit Care Med 2005; 171: 972-7.